Drug profile · INN
delafloxacin meglumine
BAXDELA
delafloxacin meglumine (BAXDELA) is a bacterial dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — delafloxacin meglumine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
delafloxacin meglumine (BAXDELA) is a bacterial dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial DNA gyrase inhibitor
Primary target: Bacterial DNA gyrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is delafloxacin meglumine?
delafloxacin meglumine (BAXDELA) is a bacterial dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for delafloxacin meglumine?
BAXDELA is a marketed brand name for delafloxacin meglumine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of delafloxacin meglumine?
delafloxacin meglumine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.